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In Brief
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survival, with potential implications for
immunotherapy.
ResourceGenomic Classification of Cutaneous Melanoma
The Cancer Genome Atlas Network1,*,*,*
1Cancer Genome Atlas Program Office, National Cancer Institute at NIH, 31 Center Drive, Bldg. 31, Suite 3A20, Bethesda, MD 20892, USA
*Correspondence: irwatson@mdanderson.org (I.R.W.), jgershen@mdanderson.org (J.E.G.), lchin@mdanderson.org (L.C.)
http://dx.doi.org/10.1016/j.cell.2015.05.044SUMMARY
We describe the landscape of genomic alterations in
cutaneous melanomas through DNA, RNA, and pro-
tein-based analysis of 333 primary and/or metastatic
melanomas from 331 patients. We establish a frame-
work for genomic classification into one of four sub-
types based on the pattern of the most prevalent
significantly mutated genes: mutant BRAF, mutant
RAS, mutantNF1, and Triple-WT (wild-type). Integra-
tive analysis reveals enrichment ofKITmutations and
focal amplifications and complex structural rear-
rangements as a feature of the Triple-WT subtype.
We found no significant outcome correlation with
genomic classification, but samples assigned a tran-
scriptomic subclass enriched for immune gene
expression associated with lymphocyte infiltrate on
pathology review and high LCK protein expression,
a T cell marker, were associated with improved pa-
tient survival. This clinicopathological and multi-
dimensional analysis suggests that the prognosis of
melanoma patients with regional metastases is
influenced by tumor stroma immunobiology, offering
insights to further personalize therapeutic decision-
making.INTRODUCTION
Diagnosis and surgical resection of early-stage primary cuta-
neous melanoma is often curative for patients with localized dis-
ease, but the prognosis is less favorable for patients with
regional metastases. Using the technique of lymphatic mapping
and sentinel lymph node (SLN) biopsy (Gershenwald and Ross,
2011), early surgical intervention for patients with microscopic
regional lymph node metastases (i.e., positive SLNs) has
recently been found useful for prognosis, may improve survival
in a subgroup of such patients, and serves to guide the use of
adjuvant therapy (Morton et al., 2014). Overall, survival has his-
torically been poor for patients with distant metastatic disease,
and response to conventional chemotherapy has been infre-
quent (Balch et al., 2009).
Hot-spot mutations in the V600 codon of BRAF (35%–50%
of melanomas) and Q61 codons (less frequently, the G12 or
G13 codon) of NRAS (10%–25%) led to the development of
highly selective kinase inhibitors that target the MAPK
pathway (Tsao et al., 2012). Recent clinical trials have pro-
vided proof of principle that therapeutic agents targeting acti-vating mutations for patients with unresectable disease and/or
distant melanoma metastases can be identified through ge-
netic analyses. The Food and Drug Administration (FDA) has
approved three such inhibitors: vemurafenib, dabrafenib, and
trametinib (McArthur and Ribas, 2013). Although antitumor re-
sponses have been dramatic, they have rarely been durable.
Additional targets and combinatorial treatment strategies are
clearly needed.
Recent studies using next-generation sequencing (NGS) have
identified additional genetic aberrations (Berger et al., 2012; Ho-
dis et al., 2012; Krauthammer et al., 2012) that provide insights
into the biological heterogeneity of melanoma and also have
potentially important implications for prognosis and therapy.
However, previous biomarker studies in melanoma have either
focused on single high-throughput platforms of large sample
sets (Hodis et al., 2012; Krauthammer et al., 2012; Winnepen-
ninckx et al., 2006) or multi-platform analyses of fewer samples
(Mann et al., 2013; Rakosy et al., 2013). No prior study has inte-
grated multi-platform data from such a large cohort of clinico-
pathologically well-annotated samples.
To address this gap, The Cancer Genome Atlas (TCGA) pro-
gram performed a systematic multi-platform characterization
of 333 cutaneous melanomas at the DNA, RNA, and protein
levels to create a catalog of somatic alterations and describe
their potential biological and clinical significance. We estab-
lished a genomic/transcriptomic framework of classification
that has potential implications for prognosis and therapy and
that may relate to recent advances in immunotherapy.RESULTS
Multi-dimensional Genomic Characterization
of Cutaneous Melanoma
Compared to most solid tumors, primary melanomas are gener-
ally small at diagnosis; and in routine clinical practice, most or all
of primary tumor tissue is used for diagnostic evaluation and is
not available for molecular analyses. Accordingly, our study
included samples from thick primaries, regional, and distant
metastatic sites.
We collected frozen tumor samples from 333 cutaneous pri-
mary and/or metastatic melanomas with matched peripheral
blood from 331 adult patients from 14 tissue source sites under
protocols approved by the relevant Institutional Review Boards.
Clinicopathological characteristics are summarized in Table
S1A. The samples consisted of 67 (20%) primary cutaneousmel-
anomas (all originating from non-glabrous skin) and 266 (80%)
metastases. Of the metastases, 212 were from regional sites
(160 from regional lymph nodes and 52 from regional skin/soft
tissue), and 35 were from distant sites (Table S1A–S1C). At initialCell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc. 1681
diagnosis, patients had primary tumors (whether or not the pri-
mary tumors were included in the TCGA molecular analyses)
that were thicker (median and mean, 2.7 mm and 4.9 mm,
respectively) than in population-based registry data (Baade
et al., 2012; Criscione and Weinstock, 2010). Matched primary
and metastatic samples were available for complete molecular
analyses from only two patients.
We performed six types of global molecular analysis: solution-
based hybrid-capture whole-exome sequencing (WES, n = 320
samples), DNA copy-number profiling by Affymetrix SNP 6.0 ar-
rays (n = 333), mRNA sequencing (n = 331), microRNA
sequencing (n = 323), DNA methylation profiling (n = 333), and
reverse-phase protein array (RPPA) expression profiling (n =
202). Complete data for all six platforms were available for a
core set of 199 samples. TERT promoter mutations at C228T
and C250T were assessed by PCR-Sanger sequencing in a sub-
set of 115 samples. Deep-coverage whole-genome sequencing
and low-pass whole-genome sequencing were performed on
subsets of 38 samples and 119 samples, respectively. Clinico-
pathological and molecular data associated with each patient
are presented in a patient-centric table (Table S1D); complete
methods and results of the analyses are described in the Supple-
mental Experimental Procedures. The standard data package
associated with this report (frozen on November 14, 2013)
is available at the GDAC Firehose (http://gdac.broadinstitute.
org/runs/stddata__2013_11_14/data/SKCM/20131114) and at
Data Portal (https://tcga-data.nci.nih.gov/docs/publications/
skcm_2015/).
Identification of Significantly Mutated Genes
WES was performed on paired tumor and germline normal
genomic DNA from 318 patients, including primary (n = 58) and
metastatic (n = 262) melanomas with a mean exon coverage of
873, adequate for detecting a single-nucleotide variant (SNV)
at an allelic fraction of 0.3 with a power of 80% (Carter et al.,
2012) (see Supplemental Experimental Procedures). In total,
we identified 228,987 mutations, including both SNVs and in-
dels. Targeted validation of 455 SNVs observed in the signifi-
cantly mutated genes (see below) in a subset of tumor DNAs
(n = 277) revealed an overall validation rate of 96% (see Supple-
mental Experimental Procedures). The mean mutation rate was
16.8 mutations/Mb, the highest reported for any cancer type
thus far analyzed by TCGA (Lawrence et al., 2013) (Figure S1A)
and corroborates findings from other NGS melanoma studies
(e.g., Hodis et al., 2012) and other ultraviolet (UV)-driven skin
cancers such as basal and squamous cell carcinomas (e.g.,
Jayaraman et al., 2014). Consistent with UV radiation’s muta-
genic role in melanoma, most samples showed a high fraction
of C>T transitions at dipyrimidines (median 77.7%; interquartile
range 69.4%–82.6%) and CC>TT mutations (median 3.9%; in-
terquartile range 2.0%–5.7%) (Figure S1A). We classified sam-
ples in which C>T transitions at dipyrimidine sites accounted
for more than 60% or CC>TT mutations more than 5% of the to-
tal mutation burden as possessing a UV signature (Brash, 2015):
44 (76%) of the 58 primary and 221 (84%) of the 262 metastatic
samples had such a signature.
Given the statistical challenge of defining significance against
a high background mutation rate, we used two algorithms to1682 Cell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc.define significantly mutated genes (SMGs): MutSig and InVEx
(Hodis et al., 2012; Lawrence et al., 2014; Lawrence et al.,
2013). MutSig takes into consideration patient-specific mutation
frequencies and spectra, mRNA expression levels, and gene-
specific DNA replication times; InVEx controls for patient-spe-
cific, gene-specific, and nucleotide-context-specific mutation
probabilities (see Supplemental Experimental Procedures).
WES analysis by InVEx identified 13 SMGs (Bonferroni p <
0.05, or 20 SMGs at Q < 0.1) by either functional mutation burden
or loss-of-function tests, all of them among the 42 SMGs identi-
fied by MutSig (Q < 0.1) (Tables S2A–S2D and Figure S1B). The
13 SMGs included previously described melanoma oncogenes
and tumor suppressors (BRAF, NRAS, CDKN2A, TP53, and
PTEN), as well as recently identified mutated genes (RAC1,
MAP2K1, PPP6C, and ARID2) (Hodis et al., 2012; Krauthammer
et al., 2012; Nikolaev et al., 2012). Our cohort also had sufficient
statistical power to annotate several previously implicated mela-
noma genes as SMGs (NF1, IDH1, and RB1) (Andersen et al.,
1993; Draper et al., 1986; Lopez et al., 2010). We also identified
DDX3X, a putative RNA helicase, as a novel candidate mela-
noma SMG (Figures 1A and S1C). SMGs with UV-induced
hot-spot mutations included RAC1 (6.9%) and IDH1 (6.2%) (Fig-
ure S1C). The RAC1 hot-spot mutation has been linked to resis-
tance to BRAF inhibitors (Van Allen et al., 2014; Watson et al.,
2014). Similar to findings in other tumor types, IDH1-mutated
samples were enriched in the high CpG islandmethylator pheno-
type (CIMP) subgroup (Figures S1D–S1G) (Noushmehr et al.,
2010).
Additionally, two genes (MRPS31 and RPS27) that encode ri-
bosomal proteins were identified by MutSig as SMGs. Both
possess presumptive UV-induced hot-spot mutations in their
50 UTR (in 5% and 9% of samples, respectively) (Fig-
ure S1H). MRPS31 encodes a mitochondrial ribosomal protein
not previously associated with cancer; RPS27 is a component
of the 40S ribosomal subunit whose overexpression has been
reported in melanoma (Santa Cruz et al., 1997). The recurrent
mutation in RPS27 was recently shown to expand the 50 TOP
element, a motif known to control mRNA translation regulated
through the PI(3)K/AKT and mTOR pathways (Dutton-Regester
et al., 2014).
Genomic Classification of Melanoma
One of the most significant successes in clinical practice has
been the development of targeted therapies for patients with
activating driver mutations (McArthur and Ribas, 2013; Tsao
et al., 2012). We therefore classified melanomas based on iden-
tified SMGs and their distribution in our cohort (n = 318 cases
with WES data; described below, Figure 1A, and Table 1) to
create a framework that could be used for personalized thera-
peutic decisions.
BRAF Subtype
The largest genomic subtype is defined by the presence of
BRAF hot-spot mutations. Of the 318, 52% (n = 166) harbored
BRAF somatic mutations. Of those, 145 targeted the well-
documented V600 amino acid residue: V600E (n = 124),
V600K (n = 18), and V600R (n = 3). The second most frequent
BRAF mutation targeted the K601 residue (n = 5). As in previ-
ous reports (Pollock et al., 2003), both BRAF V600 and K601
Figure 1. Landscape of Driver Mutations in Melanoma
(A) Total number of mutations, age at melanoma accession, and mutation subtype (BRAF, RAS [N/H/K],NF1, and Triple-WT) are indicated for each sample (top).
(Not shown are one hyper-mutated and one co-occurring NRAS BRAF hot-spot mutant). Color-coded matrix of individual mutations (specific BRAF and NRAS
mutations indicated) (middle), type of melanoma specimen (primary or metastasis), and mutation spectra for all samples (bottom) are indicated. For the two
samples with both a matched primary and metastatic sample, only the mutation information from the metastasis was included.
(B) BRAF mutations that co-occur with RAS family member and NF1 mutations are illustrated across the BRAF protein.
(C) Fraction of BRAF V600/K601E and non-V600/K601E co-occurring with the RAS (N/H/K), NF1, NF1/RAS (N/H/K) combined cohort and no NF1/RAS (N/H/K)
mutations.
(D) NF1 mutations found in melanoma whole-exome sequencing data across the NF1 protein.
(E) Fraction of NF1 missense and truncating mutations co-occurring with RAS hot-spot or non-BRAF/RAS hot-spot mutations. (Mut, mutation).
See also Figure S1.
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Table 1. Implications for Clinical Management Based on Features Identified by Comprehensive Molecular TCGA Analysis
Mutation Subtypes BRAF RAS NF1 Triple Wild-Type
1MAPK pathway 1BRAF V600, K601 1(N/H/K) RAS G12,
G13, Q61
1NF1 LoF mut; (BRAF
non-hot-spot mut)
1KIT COSMIC mut/amp,
PDGFRa amp, KDR
(VEGFR2) amp; rare
COSMIC GNA11 mut,
GNAQ mut
2Cell-cycle pathway CDKN2A mut/del/h-meth
(60%); 2(CDK4
COSMIC mut)
CDKN2A mut/del/h-meth
(70%); CCND1 amp
(10%), 2(CDK4
COSMIC mut)
CDKN2A mut/del/h-meth
(70%); RB1 mut
(10%)
CDKN2A mut/del/h-meth
(40%); CCND1 amp
(10%), 2CDK4 amp
(15%)
3DNA damage response
and cell death pathways
TP53 mut (10%);
3(note: TP53 wild-type in
90% of BRAF subtype)
TP53 mut (20%) TP53 mut (30%) 3MDM2 amp (15%);
3BCL2 upregulation
4PI3K/Akt pathway 4PTEN mut/del (20%);
4(rare AKT1/3 and
PIK3CA COSMIC mut)
4AKT3 overexpression
(40%); 4(rare AKT1/3
and PIK3CA COSMIC
mut)
4AKT3 overexpression
(30%)
4AKT3 overexpression
(20%)
5Epigenetics 5IDH1 mut, 5(rare EZH2
COSMIC mut); 5ARID2
mut (15%)
5IDH1 mut, 5(rare EZH2
COSMIC mut); 5ARID2
mut (15%)
5IDH1 mut, 5(EZH2 mut);
5ARID2 mut (30%)
5IDH1 mut, 5(rare EZH2
COSMIC mut)
Telomerase pathway Promoter mut (75%) Promoter mut (70%) Promoter mut (85%) Promoter mut (< 10%);
TERT amp (15%)
Other pathways PD-L1 amp, MITF amp,
PPP6C mut (10%)
PPP6C mut (15%)
6High immune infiltration
(pathology)
30% 25% 25% 40%
Class 1: Clinically actionable 1BRAF inhibitors; 1MEK
inhibitors
1MEK inhibitors 1C-KIT inhibitors
(imatinib, dasatinib,
nilotinib, sunitinib); PKC
inhibitors (AEB071)
2CDK inhibitors 1,2CDK inhibitors 2CDK inhibitors
3MDM2/p53 interaction
inhibitors
3MDM2/p53 interaction
inhibitors
4PI3K/Akt/mTOR inhibitors 4PI3K/Akt/mTOR inhibitors 4PI3K/Akt/mTOR inhibitors 4PI3K/Akt/mTOR inhibitors
6immunotherapies (mAb against immune checkpoint proteins, high dose bolus IL-2, interferon-a2b)
Class 2: Translationally
actionable
1ERK inhibitors 1ERK inhibitors 1MEK inhibitors;
1ERK inhibitors
5IDH1 inhibitors 5IDH1 inhibitors 5IDH1 inhibitors 5IDH1 inhibitors
5EZH2 inhibitors 5EZH2 inhibitors 5EZH2 inhibitors 5EZH2 inhibitors
(PPP6C) Aurora kinase
inhibitors
(PPP6C) Aurora kinase
inhibitors
Class 3: Pre-clinical 5ARID2 chromatin
remodelers (synthetic
lethality)
5ARID2 chromatin
remodelers (synthetic
lethality)
5ARID2 chromatin
remodelers (synthetic
lethality)
3(BCL2) BH3 mimemitcs
Prominent mechanisms of pathway alterations in BRAF, RAS, NF1 and Triple Wild-Type (WT) subtypes with potential predictive genetic alterations
indicated (1, 2, 3, 4, 5, 6) for Class 1 (clinically actionable alterations), Class 2 (translationally actionable that still require additional data [evidence] to
support use in point-of-care decision making), and Class 3 (pre-clinical evidence has demonstrated biological importance but has not yet demon-
strated clinical relevance) biomarkers. High immune infiltration (pathology) is percentage of samples in respective mutation subtype with LScores
of 5–6. Amp, amplification; del, deletion; mut, mutation, h-meth, hypermethylation.hot-spot mutations were anti-correlated with hot-spot NRAS
mutations (Fisher’s exact p < 1e15). In contrast, BRAF non-
hot-spot mutations (including eight exon 11 mutations) co-
occurred with RAS (N/H/K) hot-spot and NF1 mutations (Fig-
ures 1B and 1C).1684 Cell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc.RAS Subtype
The second major subtype is defined by the presence of RAS
hot-spot mutations, including known amino acid changes with
functional consequences, in all three RAS family members (N-,
K- and H-RAS). Overall, 28% (n = 88) had NRAS somatic
mutations. Of those, 86 had hot-spot mutations, including Q61R
(n = 35), Q61K (n = 28), Q61L (n = 11), Q61H (n = 4), 61_62QE >
HK (n = 1), G12R/D/A (n = 4), and G13R/D (n = 3). We also iden-
tified less-frequent mutations in other RAS family members,
including four hot-spot HRAS (G13D, G13S, and Q61K [n = 2])
and three KRAS (G12D, G12R, and Q61R) mutations; all were
mutually exclusive with NRAS and BRAF V600 and K601
mutations.
NF1 Subtype
The third most frequently observed SMG in the MAPK pathway
was NF1, which was mutated in 14% of samples. More than
half of its mutations were predicted to be loss-of-function (LoF)
events, including 27 nonsense, 9 splice-site, and 4 frame-shift in-
dels out of 65 mutations (InVEx LoF analysis: p = 1.8e11, Q =
9.1e12) (Figures 1D and 1E).NF1 subtype (n = 28) had the high-
est mutation prevalence (39 mutations/Mb, more than double
that of the other three subtypes). Since NF1 is a GTPase-acti-
vating protein known to downregulate RAS activity through its
intrinsic GTPase activity, LoF mutation of NF1 can be viewed
as an alternative way to activate the canonical MAPK signaling
pathway. Indeed, in this cohort, NF1 was mutated in 38.7% of
non-hot-spot BRAF/NRAS melanomas (29/75) and in 70% of
non-hot-spot BRAF/NRAS samples with a UV-signature (26/
38) (Figure 1A). Furthermore,NF1mutations were anti-correlated
with hot-spot BRAF mutations (p = 1.9e9), but not hot-spot
RAS mutations (Figure 1A).
Triple Wild-Type Subtype
We defined the Triple-WT subtype (n = 46) as a heterogeneous
subgroup characterized by a lack of hot-spot BRAF, N/H/K-
RAS, or NF1 mutations. This lack of hot-spot mutations was
not due to lower tumor purity or ploidy, since power calculation
taking into account sample-specific purity and ploidy (Carter
et al., 2012) showed that our sequencing coverage is powered
to detect sub-clonal mutations at a 6%allelic fraction on average
in Triple-WT subtype (see Supplemental Experimental Proce-
dures). To identify rare low-frequency driver mutations in this
subtype, we cross-referenced all observed SNVs to recurrently
mutated base pairs (n > 20) in the COSMIC database v60 and
identified 11 additional genes with recurrent COSMIC mutations
(Table S2E). Several COSMIC mutations, including known
drivers of uveal melanoma—GNAQ (n = 1) and GNA11 (n = 2),
KIT (n = 6), as well as CTNNB1 (n = 3) and EZH2 (n = 1)—were
found in the Triple-WT subtype.
Molecular Characteristics of the Four Genomic
Subtypes
Clinically, patients in the BRAF subtype were younger than pa-
tients in the other subtypes, while those in the NF1 subtype
were significantly older (rank sum p = 0.008). Regardless of sub-
type, patients with TP53 mutant melanomas had significantly
higher mutation counts and number of C>T transitions (rank
sum p = 1.35 e05 and p = 1.1 e05, respectively). However,
no significant difference was observed in post-accession sur-
vival (i.e., survival calculated from date of biospecimen collec-
tion/accession to date of last follow-up or death, see Supple-
mental Experimental Procedures). Therefore, we next explored
the molecular heterogeneity among these genomic subtypes
by integrative analyses.UV Signature
We noted that only 30% (14/46) of samples in the Triple-WT sub-
type harbored a UV signature, compared to 90.7% of samples
with a BRAF hot-spot mutation (136/150), 93.5% with a RAS
(N-H-K) hot-spot mutation (86/92), and 92.9% of the NF1 sub-
type (26/28) (Figure S1I) (Fisher’s exact test p = 1e15). In
contrast, Triple-WT samples had more copy-number changes
and complex structural arrangements compared to the other
groups.
Somatic Copy-Number Alterations
We assessed the patterns of somatic copy-number alteration
(CNA) across subtypes. Although global patterns of arm-level al-
terations were similar, the Triple-WT had significantly more
copy-number segments (Figures S2A and S2B) and was en-
riched for focal amplifications targeting known oncogenes. For
example, we found significant 4q12 focal amplification contain-
ing the oncogene KIT only in the Triple-WT cohort (Figure 2A).
Two other adjacent oncogenes, PDGFRA and KDR (also known
as VEGFR2), were frequently co-amplified with KIT (Figure 2B).
We also observed high-level focal CNAs containing the onco-
genes CDK4 and CCND1 (p < 0.01, FDR < 0.05), consistent
with previous studies (Curtin et al., 2005), as well as MDM2
and TERT (p < 0.05, FDR < 0.05) to be significantly enriched in
Triple-WTmelanomas (Figures 2B and 2C). In contrast, focal am-
plifications of BRAF, the melanocyte lineage-specific oncogene
MITF (p < 0.01, FDR < 0.05), and the ligand for the co-inhibitory
immune checkpoint protein PD-1, PD-L1 gene (CD274), were
observed at significant frequencies in the BRAFmutant subtype
(Figures 2, S2C, and S2D), whereas NRAS amplifications co-
occurred in tumors with NRAS mutations (Figure S2C). CD274
amplifications (which encodes PD-L1) are particularly note-
worthy given the potential clinical value of PD-L1 expression in
predicting response to PD-1 pathway inhibitors (Tumeh et al.,
2014).
Structural Rearrangements
To define fusion events, we performed an integrative analysis us-
ing copy-number (n = 333), RNA-seq (n = 331), and whole-
genome sequencing (WGS) data complemented by low-pass
(n = 119) and deep (n = 38) sequencing. In total, 224 candidate
fusion drivers were identified (Table S3A). Although there was
only one recurrent fusion (GRM8-CNTNAP2, n = 2), we discov-
ered a number of melanoma-associated genes recurrently fused
to various gene partners (Figure S2E), including BRAF (ATG7-
BRAF and TAX1BP1-BRAF), RAF1 (TRAK1-RAF1, RAF1-
AGGF1, and CLCN6-RAF1), and AKT3 (CEP170-AKT3, AKT3-
PLD5, ZEB2-AKT3, and ARHGAP30-AKT3). We also identified
three MITF fusions (MITF-FOXP1, CADM2-MITF, and
FRMD4B-MITF) and three HMGA2 fusions (PCBP2-HMGA2,
TSFM-HMGA2, andSENP1-HMGA2). Eight of the 224 candidate
driver fusions (ATG7-BRAF, TAX1BP1-BRAF, LBH-FLT4,
LCLAT1-EPHA3, TRAK1-RAF1, CLCN6-RAF1, CPSF4L-ERBB4,
and MOBKL1B-EPHB1) possessed a predicted intact kinase
domain. Although additional functional studies are required to
determine the role of these fusions in melanoma, unbiased
pathway analyses of candidate fusions suggest biological func-
tions relevant to melanoma (Tables S3B and S3C).
We saw significant enrichment for the 224 predicted fusion
drivers in the Triple-WT subtype (p = 2e04) (Figure S2F). UsingCell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc. 1685
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ShatterSeek followed by manual review (see Supplemental
Experimental Procedures), we identified complex rearrange-
ment events in 38% of samples (45/117) (Table S1D). Like fusion
events, complex structural rearrangements were enriched in the
Triple-WT subtype (11/16, Fisher’s exact test p = 0.00098),
particularly in those lacking a UV signature (7/7). Taken together
with the pattern of somatic CNAs and the lower frequency of
samples possessing a UV signature (30%), these results sug-
gest that, unlike other subtypes, other mutational processes
that involve structural rearrangement of the genome drive the
malignant phenotype of Triple-WT melanomas.
TERT Promoter Mutations
We confirmed mutually exclusive TERT promoter mutations
C228T and C250T (Horn et al., 2013; Huang et al., 2013) in
23.5% and 40.9% of the 115 samples analyzed, respectively.
Interestingly, only the C228T mutation was associated with
elevated TERTmRNA expression (rank-sum test, p = 0.001) (Fig-
ure S2G) and contrasts with glioblastoma (GBM), in which both
mutations were linked to increased expression (Brennan et al.,
2013). TERT promoter mutations were observed in 75.0% (39/
52) of BRAF, 71.9% (23/32) of RAS, and 83.3% (10/12) of NF1
subtypes but in only 6.7% (1/15) of Triple-WT (p = 8e5, Fig-
ure S2H), suggesting an alternative mechanism of TERT activa-
tion (e.g., TERT amplification or rearrangement; see above) in the
Triple-WT melanomas.
CIMP Phenotype
While a higher frequency of NRAS hot-spot mutations (OR = 2.3,
p = 0.003) and a lower frequency of BRAF hot-spot mutations
(OR = 0.4, p = 0.0008) were found in the CIMP cluster defined
by DNA methylation profiles (EEP), the strongest associations
of CIMP were with IDH1 (OR = 4.05, p = 0.005) and ARID2
(OR = 3.5, p = 0.0003) mutations (Figure S1F), both of which
are chromatin-remodeling genes. Those observations suggest
that, despite the intriguing correlations, the CIMP phenotype is
not driven by the events responsible for genotypic subtypes of
melanoma.
Signaling Pathways
Classical signaling pathway diagrams suggest that BRAF, RAS
(N/H/K), and NF1 subtypes share common downstream
signaling. We analyzed RPPA profiles of 181 cancer-related total
proteins and phosphoproteins in 200 melanoma samples to
further assess downstream signaling among subtypes. Not sur-
prisingly, components of the MAPK, PI(3)K, and apoptotic
signaling pathways were differentially activated by BRAF/
RAS(N/H/K)/NF1 driver mutations (Figures 3 and S3). Although,
for example, the upstream phospho-MAP2K1/MAP2K2 (MEK1/
2) S217/S221 was elevated in both BRAF and RAS (N/H/K)
hot-spot mutation subtypes (Figure 3A), the highest relative me-
dian activation of phospho-T202/Y204MAPK1/MAPK3 (ERK1/2)Figure 2. Landscape of Copy-Number Alterations in Melanoma
(A) GISTIC 2 analysis across four subtypes with selected highlighted genes from
(B) Fraction of BRAF, RAS (N/H/K), NF1, and Triple-WT subtypes with focal amp
KDR,MDM2, CDK4, CCND1, and TERT (right). Asterisk indicates significant incre
Fisher’s exact test (p < 0.01, FDR < 0.05).
(C) Landscape ofmutation subtypes, selected cosmicmutations, and subtype-spe
mutation subtype (BRAF, RAS, NF1, and Triple-WT) (top), color-coded matrix o
indicated) (middle), and type of melanoma specimen (primary or metastasis) and
See also Figure S2.was observed in the RAS (N/H/K) mutant subgroup (Figure 3B).
As predicted by copy-number analysis, Triple-WT tumors
showed the highest median KIT protein abundance (Figure 3C).
In contrast,NF1mutantmelanomas had the highestmedian level
of CRAF expression, highlighting differential MAPK activation in
this subtype (Figure 3D). Other examples of differential subtype-
specific signaling included higher median levels of the anti-
apoptotic protein BCL-2 in the Triple-WT subtype (Figure 3E)
and regulators of insulin signaling (IGFBP2) in BRAF hot-spot
mutants (Figure 3F). Additional proteins involved in the PI(3)K/
mTOR and epithelial-mesenchymal transition pathways were
also significantly associated with particular mutation subtypes
(Figure S3).
Molecular Pathways
To broaden our view of the commonmolecular processes dysre-
gulated in melanoma, we integrated mutation, copy-number,
and methylation data to identify recurrently targeted pathways
and signaling interactions involving significantly altered genes
in all samples (n = 318) (Figures S4A–S4D). We manually curated
the genetic alterations by BRAF, RAS (N/H/K), NF1, and Triple-
WT subtypes (Figure 4A) and found that RAS (N/H/K)-MAPK-
AKT, RB1/CDKN2A cell-cycle pathways, and MDM2/TP53
apoptosis pathways were altered in 91%, 69%, and 19% of
cases, respectively. TP53mutations were foundmore frequently
inBRAF,RAS, andNF1 tumors, compared to Triple-WT, in which
MDM2 amplifications weremore frequent. Interestingly, of the 49
TP53 mutations identified, 46 (93.9%) were found in UV signa-
ture samples. Although CDKN2A/B alterations were nearly
evenly distributed across subtypes, CDK4 and CCND1 amplifi-
cations were more frequent in Triple-WTs, and RB1 mutations
were detected in a higher fraction of NF1 subtype tumors. Of
the 12 RB1 mutations identified in this study, all were in UV
signature samples. Finally, as previously reported (Pollock
et al., 2003), PTEN mutations and deletions were more frequent
in BRAF-mutant melanomas (Figures 4A and 4B), whereas
amplification and mRNA overexpression of AKT3 were signifi-
cantly enriched in RAS (N/H/K), NF1, and Triple-WT compared
to the BRAF subtype (p < 0.05) (Figure 4B).
Transcriptomic Classification of Melanoma
We performed consensus hierarchical clustering analysis
(TCGA, 2014a) of the 1,500 genes with the most variant
expression levels in 329 samples and identified three robust
stable clusters. Based on the gene function(s) of discrimina-
tory mRNA transcripts, we named the clusters ‘‘immune’’
(n = 168; 51%), ‘‘keratin’’ (n = 102; 31%), and ‘‘MITF-low’’
(n = 59; 18%) (Figure 5A and Table S4A). Interestingly, post-
accession survival of patients with regionally metastatic tu-
mors was significantly different among the three clusterssignificant minimal common regions.
lifications determined by GISTIC 2 for BRAF and MITF (left) and KIT, PDGFRA,
ase in amplification in the indicated mutation subtype compared to the rest by
cific enriched copy-number amplifications. Per samplemutation rate, age, and
f individual mutations and amplifications (specific BRAF and NRAS mutations
mutation spectra for all samples (bottom) are shown.
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Figure 3. Analysis of Protein Expression
Levels in Melanoma Samples
Individual protein levels were determined by RPPA
across mutation subtypes.
(A) Phospho-MAP2K1/MAP2K2 (MEK1/2) S217/
S221 was elevated in both the BRAF and RAS hot-
spot mutation subtypes compared to NF1 and
Triple-WT.
(B) Only RAS hot-spot mutant samples showed
higher median levels of phospho-T202 Y204
MAPK1/MAPK3 (ERK1/2).
(C) Triple-WT melanomas had the highest median
KIT protein expression.
(D and E) (D) NF1mutant melanomas had a higher
median level of CRAF expression, and Triple-WT
had higher BCL-2 levels (E) compared to BRAF
and RAS subtypes.
(F) Median IGFBP2 levels were highest in BRAF
hot-spot mutant samples. Kruskal-Wallis test, and
the post hoc Kruskal Nemenyi test for pairwise
comparisons.
*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001,
#p = 5.4e6. See also Figure S3.(p = 0.001, Figure 5B), suggesting that these transcriptomi-
cally defined subclasses may be biologically relevant and
distinct.
‘‘Immune’’ Subclass
A significant number of genes overexpressed in this subclass
were associated with immune cell subsets (T cells, B cells,
and NK cells), immune signaling molecules, co-stimulatory
and co-inhibitory immune checkpoint proteins, cytokines, che-
mokines, and corresponding receptors (Tables S4A–S4B). As
74% (113/152) of samples in the subclass were procured
from regional lymph nodes (Pearson’s chi-square test, p <
0.001), we first assessed whether high expression of im-
mune-related genes reflected the biology of melanoma-infil-
trating immune cells or a non-specific admixture of ‘‘contami-
nating’’ adjacent lymphoid tissue in the samples (Erdag et al.,
2012). Specifically, we compared the expression of nine
curated immune gene signatures (comprising 793 genes and
detailed in Table S4B) in 172 samples from lymph nodes
and 157 tumors from other tissues (Figures S5A and S5B).
Reassuringly, there was no significant difference in expression
of tested immune signatures between the samples from lymph
nodes and non-lymph node tissues (Figure S5A), suggesting
that the transcriptomic features of the immune subclass
were not due to contaminating adjacent lymph node tissue.
Patients with regionally metastatic tumors in this subclass
showed more favorable post-accession survival than did those1688 Cell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc.in the other two subclasses (log-rank
test, p = 0.003), in accordance with pre-
vious reports of the host immune
response in melanoma (Azimi et al.,
2012).
‘‘Keratin’’ Subclass
This cluster was characterized by high
expression of genes associated with ker-
atins, pigmentation, and epithelium, aswell as genes associated with neuronal development or other or-
gan-specific embryologic development (Table S4A). Approxi-
mately 74% of primary melanomas clustered within this group
(Pearson’s chi-square test, p < 0.001) and showed high expres-
sion of genes previously reported to be elevated in primary mel-
anomas. Included were several keratins, kallikreins, and other
epidermal genes. However, 25 keratin cluster samples were
derived from regional lymph nodes, suggesting that expression
of the epithelial transcripts was not due solely to admixture of
epithelial tissue (such as skin epidermis) with melanoma tumor
tissue, at least for this organ site of procurement; indeed, kera-
tins and other epithelial markers have been found in some mela-
noma cell lines (Shields et al., 2007). Of note, regional metastatic
melanomas exhibited worse outcome when compared with
stage-matched samples assigned to the immune or MITF-low
cluster (log-rank, p = 0.0007) (Figure 5B), supporting the view
that the keratin cluster represents, at least in part, a previously
unappreciated but biologically distinct melanoma subtype with
adverse prognosis.
‘‘MITF-Low’’ Subclass
The ‘‘MITF-low’’ cluster was characterized by low expression of
genes associated with pigmentation and epithelial expression
(Table S4A), including several MITF target genes and genes
involved in immunomodulation, adhesion, migration, and extra-
cellular matrix. This cluster was significantly enriched with genes
preferentially expressed within the nervous system and/or
AB
Figure 4. Pathways Altered in Melanoma
(A) Percentage of recurrently altered pathways in the four melanoma subtypes (BRAF = V600/K601 mutants, RAS [N/H/K] = G12, G13, and Q61 mutants)
through integration of mutation, copy-number variation, and hypermethylation data are indicated (n = 316; not shown are one hyper-mutated and one co-
occurring BRAF/NRAS hot-spot mutant sample). Manual curated pathway shows percentage of TP53, CDKN2A/RB1, and MAPK/AKT pathway across all
samples (note: percentages of alterations of MAPK and AKT pathway are combined, given their high level of interconnectivity). a, amplification; d, deletion, m,
mutation.
(B) Co-occurring somatic CNAs, mutations, and mRNA expression (color code indicated on graph) for the PI(3)K/mTOR pathway across the four mutation
subtypes (left). Bar graph indicating percentage of fraction of subtypes with AKT3 activation or PTEN inactivation (right). Enrichment of a given alteration in a
subgroup is estimated by Fisher’s exact test.
See also Figure S4.associated with neuronal development or other organ-specific
embryologic development.
Integrative Molecular Subtypes
Using the iCluster algorithm (see Supplemental Experimental
Procedures), we next integrated multiple genomic dimensions
(mutation, somatic CNAs, DNA methylation, and expression) to
define molecular subtypes and to unravel hidden associations
of the various subtypes identified in each genomic dimension
(Figures 5A, S1D, S5C, and S7 and Data S1 and Table S4). We
observed clear associations between the keratin expression
subtype, the CIMP subtype, and a miRNA subgroup (cluster 3),which had a relatively lower frequency of hot-spot BRAF muta-
tions (Figure S5D, iClust 1). Conversely, ‘‘MITF-low’’ cluster sam-
ples had a higher percentage of BRAF-hot-spot mutations
(compared with ‘‘keratin’’ and ‘‘immune’’ clusters: 66% versus
33%and 45%, respectively; Fisher’s exact test, p = 0.0003 (visu-
alized in Figure S5E). In addition, a lower percentage of tumor
samples that were classified as ‘‘MITF-low’’ had no mutations
in either BRAF, NRAS, and NF1 compared with ‘‘keratin’’ and
‘‘immune’’ clusters (3% versus 21% and 14%, respectively;
Fisher’s exact test, p = 0.006) (Figure S5E). We also discerned
associations with the hypomethylation subgroup and the MITFCell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc. 1689
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Figure 5. Integrative Analysis across Multiple Molecular Data Platforms Provides Insights into the Biology and Prognostic Significance of
Immune Infiltrates in Cutaneous Melanoma
(A and B) (A) Unsupervised clustering of 329 melanoma samples using the top 1,500 genes showing the maximum absolute deviation identify three clusters
defined as ‘‘immune-high,’’ ‘‘keratin-high,’’ and ‘‘microphthalmia-associated transcription factor (MITF)-low’’ based on gene function of discriminatory mRNAs
and (B) post-accession survival curves for RNA subgroups.
(C) Distribution of lymphocytic scores determined by histopathology analysis according to sample type (described in detail in the Supplemental Experimental
Procedures).
(D) Post-accession survival curves for high and low lymphocytic infiltration scores.
(legend continued on next page)
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expression class (Figure S5D, iClust 2). Finally, we observed a
low copy-number subgroup, a normal-like methylation profile,
and enrichment for tumors possessing the immune mRNA
expression signature, consistent with the presence of lympho-
cytic infiltration (Figure S5D, iClust 3).
Clinical Significance of the Immune Transcriptomic
Subclass
Demonstrating the clinical relevance of molecular classification
requires interpretation in the context of existing clinical practice.
As a proof of concept, we addressed the clinical relevance and
potential application of the observation that the ‘‘immune’’ tran-
scriptomic subclass was associated with improved post-acces-
sion survival of patients with regional metastatic melanoma.
Although tumor-infiltrating lymphocytes have been associated
with favorable prognosis inprimarymelanoma (Azimi et al., 2012),
such an association has not been investigated in regional dis-
ease. To assesswhether our transcriptomic classification ofmel-
anoma captures the biology of tumor-associated lymphocytes,
we complemented the clinicopathological annotation provided
by tissue source sites with a standardized pathology review of
frozen section slides by TCGA Analysis Working Group (AWG)
dermatopathologists (see Author Contributions); the density
and distribution of melanoma-associated lymphocytes were
used to derive a ‘‘lymphocyte score’’ (LScore), a semiquantitative
measure of the number of lymphocytes in a sample (see Supple-
mental Experimental Procedures). Additional histopathological
parameters includedpercent tumor content, percent necrotic tis-
sue, and amount of melanin pigment. Melanomas from regional
or distant lymph nodes showed significantly higher LScore than
tumors from other tissues (Wilcoxon rank-sum test, p = 5.6e8;
Figure 5C). Among the subgroup of regional metastatic mela-
nomas, elevated LScore was significantly associated with pro-
longed post-accession survival (Figure 5D), corroborating prior
observations that tumor-associated lymphocytes are a favorable
prognostic factor in melanoma (Bogunovic et al., 2009; Mihm
et al., 1996). Remarkably, there was a striking concordance be-
tween high LScore (3–6) and assignment to the immune subclass
(Figure S6A) (Fisher’s exact test, p < 1e12).
Next, we asked whether transcriptomic features that defined
the ‘‘immune’’ cluster are seen at the protein level by RPPA. In
particular, we focused on two immune-related proteins, LCK
and SYK, non-receptor tyrosine kinases commonly associated
with T- and B-lymphocyte signaling. Interestingly, unsupervised
clustering of RPPA data revealed that LCK and SYK are highly
expressed in a subset of samples (Figure S5C) that are enriched
with tumors in the transcriptomic immune subclass and/or that
have high LScores (Figure 5E). However, high LCK, but not
SYK, protein expressionwas also strongly associatedwith favor-
able post-accession survival of patients with regionally metasta-
tic tumors (Figure 5F and data not shown). Tumors with high
LScores tended to be assigned to the transcriptomic immune(E) Overlap of LCK high and low protein expression obtained from RPPA data w
subgroups determined by mRNA clustering analysis.
(F) Association of LCK protein with post-accession survival. Three curves describ
rank test).
See also Figures S5, S6, and S7 and Data S1.subclass and also express elevated levels of LCK protein (Fig-
ures S6A and S6B). These three characteristics overlapped
considerably, and a combination of the three predicted mela-
noma outcome more accurately than did any one of the features
alone (log-rank, p = 8.0e6, post-accession survival in regionally
metastatic tumors; Figure S6C). This observation is consistent
with the hypothesis that the three reflect unique (although over-
lapping) biological characteristics, each of which confers favor-
able outcomes in melanoma.
Finally, recognizing that unsupervised cluster analysis of a
transcriptomic profile is not readily applicable to clinical practice,
we tested the hypothesis that a bivariate model of LScore and
LCK protein expression level offers a comparable prognostic
prediction. Indeed, tumors with high LScore and high LCK
expression were associated with significantly improved post-
accession survival compared with those having low LScore
and low LCK expression (log-rank p = 7.9e5, hazard ratio =
5.5, tumors with both high LScore and LCK versus both scores
low; Figure S6D). Multivariable Cox proportional hazard regres-
sion also demonstrated that both LScore and LCK expression
have independent predictive value in the two-factor model (Fig-
ure S6E). Overall, this integrative analysis suggests that a com-
bination of LCK protein expression and pathologists’ scoring of
tumor-infiltrating lymphocytes may be more prognostic for pa-
tientswith nodalmetastases than assessment of tumor-infiltrating
lymphocytes alone.
DISCUSSION
We propose here that cutaneous melanomas can be divided into
four genomic subtypes, designated BRAF, RAS (N/H/K), NF1,
and Triple-WT. Such a genomic classification provides a frame-
work for exploring how additional molecular alterations may
explain observed biological and clinical differences among the
subtypes. It also provides signposts for identification of drug-
able targets and predictive biomarkers, as well as potentially
useful guidance for decisions about therapy.
Based on evidence that (1) BRAF/RAS (N/H/K) mutant mela-
nomas are driven, at least in part, by MAPK signaling (Hodis
et al., 2012; Krauthammer et al., 2012); (2) melanomas lacking
NF1 expression are dependent on MAPK signaling and respond
to MAPK inhibitors (Maertens et al., 2013; Nissan et al., 2014);
and (3) there are clinicopathologic and molecular differences
among melanomas that do not have hot-spot mutations in
BRAF/RAS but differ with respect to NF1mutation status, mela-
noma joins two other RTK/RAS-driven solid tumor types (GBM
and lung adenocarcinoma) analyzed by the TCGA, among which
a subset of these cancers has loss-of-function NF1 mutations
(TCGA, 2008, 2014b).
We suggest that significantly mutated genes and other molec-
ular alterations identified here, combined with previously
described melanoma-associated genes, are likely to haveith lymphocytic infiltration scores determined by pathology and RNA immune
e cumulative survival rates of three tertile patient subsets (p = 0.007 with log-
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important implications for prognosis and therapy (Table 1). For
example, we postulate that patients with BRAF wild-type, NF1
mutant melanomas respond to MEK and/or ERK inhibitors
(Maertens et al., 2013; Nissan et al., 2014; Whittaker et al.,
2013), supported by cell line studies that demonstrate that at
least someNF1mutant cell lines respond toMEK inhibitors (Ran-
zani et al., 2015). In the setting of frequently co-occurring NF1
and ARID2 mutations, synthetic lethal strategies targeting chro-
matin modifiers represent a rational area for pre-clinical research
(Helming et al., 2014). In addition to therapeutic strategies
currently under clinical development, melanomas with RAS
(N/H/K) mutations, frequently concurrent with PPP6C hot-spot
mutations, may provide therapeutic opportunities for combina-
torial treatment strategies that include Aurora kinase inhibition
(Gold et al., 2014). Previous studies have shown frequent co-
occurrence of BRAFmutations and PTENmutations or deletions
(Tsao et al., 2012). Here, we showed a higher frequency of ampli-
fications and overexpression of AKT3 in RAS, NF1, and Triple-
WT melanomas, which may provide additional biomarkers to
support the use of combination MEK and PI(3)K/AKT/mTOR
pathway inhibitors in such subtypes. In addition, mutations in
PIK3CA (E545K, H1047L) and AKT1/3 (E17K) in BRAF, as well
asRAS (N/H/K)mutantmelanoma (Table S2E), may serve as bio-
markers that predict response to the above-mentioned targeted
therapies.
Candidate driver events in Triple-WT melanomas provide op-
portunities for pre-clinical and clinical efforts to effectively target
these molecular aberrations. These include KIT mutations/am-
plifications, co-amplified RTKs, PDGFRA and KDR (VEGFR2),
and even rare GNAQ Q209P (n = 1) and GNA11 Q209L (n = 2)
mutations (sample IDs: TCGA-ER-A3ES, TCGA-ER-A3ET, and
TCGA-ER-A2NF)—the latter of which, interestingly, co-occur
with hot-spot SF3B1 R625H mutations (n = 2 for co-occurrence
with GNA11/Q hot-spot mutations) in our cutaneous melanoma
cohort, but not BAP1 mutations, which are frequently found in
metastatic uveal melanoma (Field and Harbour, 2014). Although
GNAQ and GNA11 hot-spot mutations are common in uveal
melanomas, they have also been reported in blue nevi and pri-
mary melanocytic neoplasms of the central nervous system
(Ku¨sters-Vandevelde et al., 2010). Our classification supports
the use of imatinib and dasatinib to treat patients with KIT-
mutated/amplified cutaneous melanomas (Carvajal et al.,
2011; Hodi et al., 2008; Lutzky et al., 2008; Terheyden et al.,
2010) and consideration of combination therapies with sorafe-
nib, crenolanib, regorafenib, and pazopanib to target co-ampli-
fied RTKs, PDGFRA, and KDR (VEGFR2). Triple-WT melanomas
with amplifications of MDM2 and overexpression of BCL2 may
respond to inhibitors such as AMG 232, nutlin-3, and BH3 mi-
metics, currently in preclinical or clinical development in mela-
noma. Such agents may also be beneficial for patients with
wild-type TP53 across the genetic subtypes (Frederick et al.,
2014; Ji et al., 2013; Sun et al., 2014). Other potentially action-
able mutations include recurrent IDH1 R132 (6%) and EZH2
Y641 mutations (<1%) (Table S2E).
Overall, approximately half of all cases were assigned to the
‘‘immune’’ subtype. Interestingly, the response rate to inhibitors
of the PD-1/PD-L1 pathway is approximately one-third (Brahmer
et al., 2012; Hamid et al., 2013; Topalian et al., 2012). In our1692 Cell 161, 1681–1696, June 18, 2015 ª2015 Elsevier Inc.study, expression of both PD-1 and PD-L1 was significantly
higher in ‘‘immune’’ compared to each of the two other groups
(Figure S6F), similar to a recent report showing that pre-existing
CD8+ T cells distinctly located at the invasive tumor margin are
associated with immunohistochemical expression of PD-1 and
PD-L1, and was also predictive of response to pembrolizumab
(Tumeh et al., 2014). However, it is important to emphasize
that our data do not prove that the immune subtype represents
a population responsive to immunotherapies.
We show that immune infiltration is statistically correlated with
more favorable prognosis, irrespective of genomic subtype. The
lack of a genomic correlation with outcome provides a plausible
molecular explanation for the lack of observed preferential anti-
tumor responses in clinical trials employing immune checkpoint
blockade, at least in relation to BRAF status (Ascierto et al.,
2014; Robert et al., 2014). Nonetheless, despite these data,
the question of whether specific mutated melanoma antigens
are responsible for differences in the degree of tumor infiltration
by lymphocytes is an area of active investigation (Robbins et al.,
2013; Snyder et al., 2014). Our combined RPPA analysis,
including exploration of LCK and SYK proteins that are associ-
ated with T cell and B cell signaling effectors, respectively,
suggests that T cell, but not B cell, signaling has prognostic sig-
nificance. This relevance of T cells, and in particular effector
CD8+ T cells, is congruent with clinical benefit seen with high-
dose bolus IL-2, a T cell growth factor used as a therapeutic
agent for advanced melanoma (McArthur and Ribas, 2013).
Among the cohort of patients in this study with advanced
stage III disease (Balch et al., 2010), high lymphocytic score
and immune-associated gene expression was associated with
prolonged post-accession survival, potentially reflecting a clin-
ical benefit of immunotherapies for stage III melanoma patients
(Eggermont et al., 2008; Kirkwood et al., 1996). Such markers
should be considered for further evaluation and potential inte-
gration into future AJCC staging systems and associated prog-
nostic models, as well as for exploration as a potential predictor
of response to adjuvant therapies for stage III disease.
EXPERIMENTAL PROCEDURES
Patients and Biospecimens
Eligible patients had a diagnosis of either primary or metastatic cutaneous
melanoma or metastatic melanoma of unknown primary (Balch et al., 2009;
Dasgupta et al., 1963), but no previous systemic therapy (except that adjuvant
interferon-a R90 days prior was permitted); the site from which the bio-
specimen was collected could not have been previously treated at any time
with radiotherapy. Biospecimens from resected primary and/or metastatic
melanomas were obtained from patients with appropriate informed consent
and institutional review board or ethics board approval. Biospecimens were
classified as either primary or metastatic based on the available clinical and
pathological information. Independent pathological review confirmed that
each biospecimen was consistent with melanoma. As specimens were
required to have sufficient mass and quality for downstream molecular
analyses, those from advanced primary and/or metastatic tumors were over-
represented. The complete methodology for patient eligibility, clinical and
pathological data elements, biospecimen acquisition, and molecular analyte
extraction is described in the Supplemental Experimental Procedures.
Data Generation
Data from at least one platform were available for 333 patients. The data types
included: (1) clinical, (2) whole-exome sequencing, (3) DNA copy-number and
single-nucleotide polymorphism array, (4) whole-genome sequencing, (5)
RNA-sequencing data, (6) DNA methylation, (7) reverse-phase protein array,
and (8) microRNA sequencing. Details of data generation and analyses are
described in the Supplemental Experimental Procedures. All data sets are
available through the Cancer Genome Atlas (TCGA) data portal (https://
tcga-data.nci.nih.gov/tcga).
Whole-Genome and Exome-Sequencing Data Analysis
Whole-exome sequencing was performed as previously described (TCGA,
2012). Exome capture was performed using the Agilent Sure-Select Human
All Exon v2.0, 44 Mb kit, followed by 2 3 76 bp paired-end sequencing on
the Illumina HiSeq platform. Read alignment and processing were performed
using BWA and the Picard and Firehose pipelines at the Broad Institute. For
each file, Picard generates a single BAM file that includes reads, calibrated
quantities, and alignments to the genome. The Firehose pipeline performs
quality control, local realignment, mutation calling, small insertion and deletion
identification, and coverage calculations, among other analyses. Complete
details of the pipeline can be found online at http://www.broadinstitute.org/
cancer/cga. Whole-genome sequencing methods are described in detail in
the Supplemental Experimental Procedures.
RNA-Sequencing Data Analysis
Total RNA was converted to mRNA libraries using the lllumina mRNA TruSeq
kit, following the manufacturer’s directions. Libraries were sequenced on the
Illumina HiSeq 2000 as previously described (TCGA, 2012). Read mapping,
gene expression quantitation, and identification of fusion transcripts are
described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, four tables, and one data file and can be found with this article
online at http://dx.doi.org/10.1016/j.cell.2015.05.044.
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